serena williams opens up about being on a glp 1 Using GLP-1 In Her Weight Loss Journey Serena Williams Opens Up About

doi: 10.1007/s12020-024-03998-8, 55

Referral Links for What Exactly Is Retatrutide? Learn more about GLP-1/GIP/Glucagon triple-agonist therapies TripleHormone-Receptor Agonist Retatrutide for Obesity See how Retatrutide compares to Semaglutide & Tirzepatide Eli Lilly Overview of Retatrutide Mechanism & Research Background on Triple-Agonist Peptide Development Scientific Review: Triple-Hormone Agonists for Obesity Safety profile and metabolic benefits overview PubMed: Retatrutide Safety, Tolerability & Metabolic Outcomes Patient-friendly explanation of emerging weight-loss peptides FDAs Concerns with Unapproved GLP-1 Drugs Used for Weight Loss Before & After Transformations Real Patient Results Real people, REAL RESULTS

Retatrutide does not yet have dedicated cardiovascular or renal outcome trials, though Phase 3 studies evaluating these endpoints are currently enrolling participants with expected completion in 2026

People with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasias should not take GLP-1 medications

Metabolism and fat-burning ingredient patches These patches are designed to increase fat breakdown or energy use and often include compounds involved in metabolism

Exenatide (Byetta): risk of severe pancreatitis and renal failure